NextCure NXTC

NASDAQ NXTC
$6.40 +0.17 (+2.73%)
At close: Nov 13, 2026 · 4:00 PM EST

NextCure (NXTC) stock price is $6.40, up 2.73% on the day, as of Nov 13, 2026. It has a market cap of $29.30Mn, and is classified in the Biotechnology industry (Healthcare sector).

Key Stats
Market Cap29.30 Mn
P/E-0.83
FCF (Yr)-49.61 Mn
ROA (Yr)-85.20
EV to EBIT1.70
Net Income (Yr)-55.84 Mn
Enterprise Value-71.08 Mn
Add ratio to table…

About

NextCure is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates for cancer patients who have not responded to or have progressed on existing therapies. The company concentrates on two validated targets CDH6 and B7 H4 using distinct payloads a topoisomerase 1 inhibitor and a tubulin inhibitor. Its lead candidate SIM0505 is an antibody drug conjugate directed to CDH6 that employs a proprietary topoisomerase 1 inhibitor payload and a gly…

Read more ↓
Sector: Healthcare Sector rationale NextCure is a clinical-stage biopharmaceutical company developing antibody drug conjugates (such as SIM0505 and LNCB74) for cancer patients. Its revenue model is based on licensing and collaboration agreements (upfront and milestone payments) for the development of medical therapies, which falls squarely within the Biotechnology and Pharmaceuticals industries of the Healthcare sector. Industry: Biotechnology Biotechnology Primary NextCure is a clinical-stage biopharmaceutical company developing antibody drug conjugates (ADCs), which are biologic therapies. Its revenue is derived from collaboration and milestone payments, such as the $12 million upfront payment from Zaiming, and potential royalties on biologic product sales. Classified using BQ-MICS CIK: 0001661059

Type of Arrangement and Non-arrangement Transactions Breakdown of Revenue (2020)

History
Peer percentiles

How NextCure ranks

Ranked against the 695 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 14, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/ENegative earnings −0.83xMedian 17.0x 23rd
  • P/FCFNegative free cash flow −0.68xMedian 19.0x 16th
  • P/Operating cash flowNegative operating cash flow −0.68xMedian 16.4x 17th
  • P/S —Median 8.38x No data —
  • P/B 5.32xMedian 2.04x 23rd
  • P/Tangible book 5.32xMedian 2.31x 25th
  • EV/EBITDANegative EBITDA −0.50xMedian 14.6x 13th
  • EV/EBITNegative EBIT −0.49xMedian 18.4x 15th
  • EV/Revenue —Median 6.34x No data —
  • EV/FCFNegative free cash flow −0.48xMedian 23.4x 11th
  • EV/Operating cash flowNegative operating cash flow −0.48xMedian 19.3x 11th
  • PEG (3Y EPS CAGR)Negative earnings −0.02Median 0.43 Not meaningful —
Peer group

Peer Comparison

Companies in the Biotechnology
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 LLY ELI LILLY & Co 1,359.75 Bn46.7415.7349.50 Bn
2 JNJ Johnson & Johnson 688.76 Bn42.836.9344.65 Bn
3 ABBV AbbVie Inc. 521.69 Bn50.487.9080.90 Bn
4 MRK Merck & Co., Inc. 364.31 Bn148.685.4153.78 Bn
5 NVS Novartis Ag 306.35 Bn17.915.08-
6 AZN Astrazeneca Plc 285.96 Bn25.924.82-6.68 Bn
7 AMGN Amgen Inc 251.88 Bn26.836.4754.01 Bn
8 NXTC NextCure, Inc. 0.03 Bn-0.83--